Leerink Partnrs Forecasts Higher Earnings for Exact Sciences

Exact Sciences Co. (NASDAQ:EXAS) – Equities researchers at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for Exact Sciences in a report issued on Monday, April 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of $0.17 for the quarter, up from their previous forecast of $0.12. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.23. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The firm had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million.

A number of other research firms have also recently commented on EXAS. Mizuho began coverage on Exact Sciences in a research report on Thursday, April 10th. They set an “outperform” rating and a $60.00 price objective for the company. Guggenheim reaffirmed a “buy” rating and set a $60.00 price target on shares of Exact Sciences in a research report on Friday, April 11th. William Blair reissued an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Benchmark reaffirmed a “buy” rating and set a $65.00 target price on shares of Exact Sciences in a report on Monday, January 13th. Finally, Bank of America decreased their price target on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, February 20th. Two analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $69.25.

Exact Sciences Price Performance

Shares of EXAS opened at $44.15 on Tuesday. The firm has a fifty day simple moving average of $45.60 and a two-hundred day simple moving average of $54.62. The firm has a market cap of $8.20 billion, a PE ratio of -7.93 and a beta of 1.14. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. Exact Sciences has a 1-year low of $39.97 and a 1-year high of $72.83.

Hedge Funds Weigh In On Exact Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Asset Planning Inc bought a new position in shares of Exact Sciences during the 4th quarter valued at about $40,000. Modus Advisors LLC bought a new position in Exact Sciences during the fourth quarter valued at approximately $43,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Exact Sciences during the 4th quarter valued at approximately $45,000. AlphaQuest LLC increased its stake in Exact Sciences by 22,825.0% in the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after acquiring an additional 913 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Exact Sciences during the 4th quarter worth approximately $66,000. Institutional investors own 88.82% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.